Sensus Healthcare Inc. reported its financial results for the first quarter of 2025, revealing revenues of $8.3 million. The company faced a net loss of $2.6 million. During this period, Sensus Healthcare shipped 21 superficial radiotherapy $(SRT)$ systems, with 15 units delivered to a large customer and one unit shipped internationally. The company noted a 65% increase in treatment volume from FDA-based systems compared to the previous quarter. Sensus Healthcare emphasized its strategic investment in research and development, including efforts to promote the value of IG-SRT technology. Additionally, the company highlighted the finalization of its TransDermal Infusion $(TDI)$ product with Sentinel™ IT Solutions capabilities. The company remains optimistic about its financial outlook, projecting profitability in each of the next three quarters and for the full year. To support growth, Sensus Healthcare participated in major dermatology conferences, including the 2025 Winter Clinical Dermatology Conference and the American Academy of Dermatology Annual Meeting, where it showcased its SRT systems and pre-commercial products. The company also announced plans to expand its presence by attending smaller dermatology conferences to increase awareness of its Fair Deal Agreement (FDA) program.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.